Navigation Links
FDA Approves Vanda Pharmaceuticals' Fanapt(TM) for the Treatment of Schizophrenia
Date:5/6/2009

ROCKVILLE, Md., May 6 /PRNewswire-FirstCall/ -- Vanda Pharmaceuticals Inc. (Nasdaq: VNDA) announced today that the US Food and Drug Administration (FDA) has granted marketing approval of Fanapt(TM) (iloperidone) for the acute treatment of adult patients with schizophrenia. The approval was supported by two placebo-controlled Phase III clinical studies comparing Fanapt(TM) to placebo and active control in patients with schizophrenia, as well as safety data from more than 3,000 patients.

Fanapt(TM) is a mixed dopamine D2 / serotonin 5HT2A receptor antagonist, and belongs to the class of atypical antipsychotics.

"The approval of Fanapt(TM) marks a new opportunity for many patients with schizophrenia, who experience only partial responses to current therapies, to achieve better control of their symptoms," remarked Dr. Peter J. Weiden, Professor of Psychiatry and Director of the Psychotic Disorders Program at the University of Illinois at Chicago. "Having Fanapt(TM) available is a major help for our patients in offering an effective antipsychotic with an excellent side effect profile across a wide range of major tolerability problems associated with other antipsychotic therapies."

The efficacy of Fanapt(TM) for the treatment of schizophrenia was supported by two placebo-controlled short-term (4- and 6-week) trials. Both trials enrolled patients who met the DSM-III/IV criteria for schizophrenia, and Fanapt(TM) was shown to be superior to placebo in controlling symptoms of schizophrenia across doses of 12mg to 24mg per day. The recommended target dose range of Fanapt(TM) is 12mg to 24 mg per day. Titration to the target dose of 12mg per day can be achieved in 4 days.

Vanda plans to make Fanapt(TM) available in pharmacies later this year.

"Fanapt(TM) is an important option for
'/>"/>

SOURCE Vanda Pharmaceuticals Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. FDA Approves an Expanded Indication for Peginterferon-Based Combination Therapy for Patients With Chronic Hepatitis C
2. FDA Approves LUSEDRA(TM) (fospropofol disodium) Injection for Monitored Anesthesia Care (MAC) Sedation
3. FDA Approves Tapentadol Immediate-Release Tablets for Relief of Moderate to Severe Acute Pain
4. FDA Approves Promacta(R) (Eltrombopag), the First Oral Medication to Increase Platelet Production for People With Serious Blood Disorder
5. FDA Approves Rapid-Acting Insulin Apidra(R) for Treatment of Children with Diabetes
6. FDA Approves Bayer HealthCares Kogenate(R) FS Treatment for Routine Prophylaxis in Children with Hemophilia A
7. F.D.A. Approves SANCUSO(R), the First and Only Patch for Preventing Nausea and Vomiting in Cancer Patients Undergoing Chemotherapy
8. FDA Approves First Hepatitis B Viral Load Test
9. U.S. FDA Approves Requip(R) XL(TM), the First and Only Oral Once-Daily Non-Ergot Dopamine Agonist for Parkinsons Disease
10. EPA Approves XDS-CALUX(R) as Alternate Dioxin Test Method 4435
11. FDA Approves HIFU Clinical Trial for Recurrent Prostate Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/25/2014)... SANTA ROSA, Calif. , Oct. 24, 2014 /PRNewswire-USNewswire/ ... he was ordering large quantities of multiple controlled substances, ... patient care. They also reported that Dr. Gurney was ... Medical Board reported that one of his employees said ... his care and treatment of patients." Dr. ...
(Date:10/25/2014)... Burzynski Research Institute, Inc. (BRI) announced today that the ... company permission to conduct an open-label study of Antineoplastons ... age with a diffuse intrinsic brainstem glioma (DIPG). Study ... groups based on their age and whether or not ... study endpoint is a decrease in the size of ...
(Date:10/22/2014)... , Oct. 22, 2014  Cephasonics, a technology-innovation ... introduction of the cQUB™-1 (cQuest Ultrasound Box™-1), the first ... systems designed and manufactured by Cephasonics for purchase by ... model number. Cephasonics will be showcasing the cQUB-1 for ... this week in Chongqing, China ...
Breaking Medicine Technology:Doctors That Harm: The Real Stories Insurance Companies Against Prop 46 Don't Want You To Know, Part 8 of Consumer Watchdog Campaign Series 2Doctors That Harm: The Real Stories Insurance Companies Against Prop 46 Don't Want You To Know, Part 8 of Consumer Watchdog Campaign Series 3Burzynski Research Institute, Inc. Announces FDA Permission to Launch a New Clinical Trial in Diffuse Intrinsic Brainstem Glioma 2Cephasonics Launches the cQUB-1, First Product in New Family of cQUB White-Label Ultrasound Systems Targeted at Medical Applications 2Cephasonics Launches the cQUB-1, First Product in New Family of cQUB White-Label Ultrasound Systems Targeted at Medical Applications 3
... , Inc., a full-service contract research organization (CRO), and ... combat the growing issue of antibiotic resistance, have partnered ... walk to benefit the Cystic Fibrosis (CF) Foundation through ... Aptalis Pharma) are also working together on clinical trials ...
... May 2, 2012  Neurocrine Biosciences, Inc. (NASDAQ: NBIX ... March 31, 2012.  For the first quarter of 2012, the ... per share, compared with a net income of $2.9 million, ... 2011. This $3.8 million change in operating results is primarily ...
Cached Medicine Technology:Synteract and Rempex Partner in "Great Strides" Walk to Support Cystic Fibrosis Cure 2Neurocrine Biosciences Reports First Quarter 2012 Results 2Neurocrine Biosciences Reports First Quarter 2012 Results 3Neurocrine Biosciences Reports First Quarter 2012 Results 4Neurocrine Biosciences Reports First Quarter 2012 Results 5Neurocrine Biosciences Reports First Quarter 2012 Results 6
(Date:10/25/2014)... shorter, darker days can trigger a type of depression, ... People affected by seasonal affective disorder, also ... even have trouble getting out of bed. In extreme ... Halaris, a professor in the department of psychiatry and ... Medicine. "Seasonal affective disorder should not be taken ...
(Date:10/22/2014)... October 22, 2014 On Saturday, October 25, ... fourth annual family health and fitness fair ¡Vive tu vida! ... activity and good nutrition for better health and wellness for ... is free and open to the public, will be held ... from 9:00 am to 1:00 pm. , “¡Vive tu ...
(Date:10/22/2014)... Medical Solutions , the nation’s ... announce that our co-founder and CFO, Scott Anderson, ... 100 for 2014. Anderson was also named to ... in the staffing industry,” in 2013.     , Under ... staffing company in the U.S., was named a ...
(Date:10/22/2014)... (PRWEB) October 22, 2014 For Dr. Iris ... make money; it’s an extension of her life’s mission. Her ... venture as the owner of FirstLight HomeCare, make it clear ... important to me that my work makes a difference in ... an entrepreneurial spirit, so after much research, I felt ready ...
(Date:10/22/2014)... TUESDAY, Oct. 21, 2014 (HealthDay News) -- The ... passengers arriving from Ebola-affected nations of West Africa ... screen them for infection with the virus. ... Jeh Johnson noted that 94 percent of air ... land at one of these five airports -- ...
Breaking Medicine News(10 mins):Health News:Dark Days Here for Folks With Seasonal Depression 2Health News:Brownsville Community Health Center Presents Fourth Annual ¡Vive Tu Vida! Get Up! Get Moving!® Event 2Health News:Brownsville Community Health Center Presents Fourth Annual ¡Vive Tu Vida! Get Up! Get Moving!® Event 3Health News:Brownsville Community Health Center Presents Fourth Annual ¡Vive Tu Vida! Get Up! Get Moving!® Event 4Health News:Medical Solutions Co-Founder/CFO Scott Anderson Named to Staffing Industry Analysts’ 2014 Staffing 100 2Health News:Medical Solutions Co-Founder/CFO Scott Anderson Named to Staffing Industry Analysts’ 2014 Staffing 100 3Health News:Dr. Iris Hunter to Host Grand Opening of FirstLight HomeCare Tomorrow 2Health News:Passengers From Ebola-Affected Countries Must Land at Designated U.S. Airports 2Health News:Passengers From Ebola-Affected Countries Must Land at Designated U.S. Airports 3
... better control of disease when chemo is targeted to specific ... The number one cancer killer, lung cancer, may be more ... tumors with key genetic traits, a new study finds. , ... that, overall, 46 percent of patients with stage IV (advanced) ...
... from a sentinel lymph node removed during surgery is a ... false negatives, which means the node, when analyzed under a ... occur in the patient. The sentinel node is the first ... Now, researchers from Georgetown Lombardi Comprehensive Center say that they ...
... ... a Build-a-Beam interactive feature, Keilhauer,s new microsite for Beam Seating makes specifying beam seating ... ... and Simple Beam seating expand the original series to such an extent it can ...
... ... restrictions, and more severe problems, like sleep apnea, can increase the risk of heart attack ... Denver, ... are diagnosed with sinusitis, and many of these people find long-term relief and a new ...
... ... ... 18, 2010 -- Allegheny Medical Integrated Health Services ( http://www.alleghenymedical.com/ ), one of Pittsburgh,s ... mission is to build better health for every aspect of an individual,s life. ...
... ... Touchstone Products LLC is proud to announce the unveiling of its ... affordable prices directly to the American Consumer. TouchstoneSaunas.com offers premium ... your home. Constructed from the highest quality materials to provide ...
Cached Medicine News:Health News:Matching Tumor Types to Drugs Boosts Lung Cancer Outcomes 2Health News:Matching Tumor Types to Drugs Boosts Lung Cancer Outcomes 3Health News:Routine breast cancer biopsy might predict lymph node cancer spread 2Health News:Keilhauer's Expanded Beam Seating Launches With its Own Microsite 2Health News:Keilhauer's Expanded Beam Seating Launches With its Own Microsite 3Health News:Breathing Obstructions Caused by Sinusitis can Require Surgery, says Denver's Nose Doc 2Health News:Breathing Obstructions Caused by Sinusitis can Require Surgery, says Denver's Nose Doc 3Health News:Allegheny Medical's Occupational Health Services Helps Employers Build a Healthier Workforce 2Health News:Allegheny Medical's Occupational Health Services Helps Employers Build a Healthier Workforce 3Health News:Touchstone Saunas Goes Online to Provide Premium Quality Infrared Saunas 2
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: